{"id":868693,"date":"2025-07-10T17:09:31","date_gmt":"2025-07-10T21:09:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/"},"modified":"2025-07-10T17:09:31","modified_gmt":"2025-07-10T21:09:31","slug":"sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/","title":{"rendered":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, July  10, 2025  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>Sarepta Therapeutics, Inc. (NASDAQ: SRPT).<\/strong><\/p>\n<p>Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22jKQ68RSwOUcz0zFLoVXbCMfLrsVHXk5TyTK6hZYthL6SDQq-rkTFFXYDf7uLQyJwHKiro4S4TIqzrBMucpI1-IcZrAgG2NNh9U0ybJ1C5GlSHAWLC2trtoOiZQNYW6lZtaa8wcm8wOPVZno-sithdlOt9Ga04SvmH0ujEOhqPB2q47ojDkVpE45tuVqrorMK_amtswYUQDxTHIGesXSqBkZWhJ9R9tutxl-XCWFOXjiVv9_14hFOuOIZDL1ErPNlkWpEnhb9-OK4UKAWHbZQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/sarepta-loss-submission-form\/?id=156044&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>June 22, 2023 to June 24, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy\u2019s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and\/or lacked a reasonable basis for, their positive statements.<\/p>\n<p>\n        <strong>DEADLINE: August 25, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22jKQ68RSwOUcz0zFLoVXbCMfLrsVHXk5TyTK6hZYthL6SDQq-rkTFFXYDf7uLQyJwHKiro4S4TIqzrBMucpI1-IcZrAgG2NNh9U0ybJ1C5GlSHAWLC2trtoOiZQNYW6br8fhSXtV_FGsNgFdxkN5iakK4iRV7awmNP3tg0xaLjERkvdmRxefHAKTJ2yHNs6D8vacwXwm6CNksvxJ0Qjv7mWYVxqp7uxq3dIIeuPU0NPYujwp4c-e1xuvjB9iVBw36HBzTWwwVZWeedPA4aLWw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/sarepta-loss-submission-form\/?id=156044&amp;from=3<\/a>\u00a0<\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OU8e-pubLGKsfYnJ8jtZ1284RGB4-rqD52G43C7kymKMe-i6s8JoJr7w64aLMhN_wPDTuZ6GlJC1KOiX5uUwiteFnxWrlhupcOBPM9wPFv7PdXpAc3OrFn3piVr3uWeG\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmUxMDFjOWMtNzc0NC00MjA3LWE5NGYtZmUwZTVkYTNlMmJjLTEyNzA0NjctMjAyNS0wNy0xMC1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/sarepta-loss-submission-form\/?id=156044&amp;from=3 CLASS PERIOD: June 22, 2023 to June 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868693","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/sarepta-loss-submission-form\/?id=156044&amp;from=3 CLASS PERIOD: June 22, 2023 to June 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the &hellip; Continue reading &quot;Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T21:09:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT\",\"datePublished\":\"2025-07-10T21:09:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"},\"wordCount\":411,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/\",\"name\":\"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\",\"datePublished\":\"2025-07-10T21:09:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk","og_description":"NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/sarepta-loss-submission-form\/?id=156044&amp;from=3 CLASS PERIOD: June 22, 2023 to June 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the &hellip; Continue reading \"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-10T21:09:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT","datePublished":"2025-07-10T21:09:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/"},"wordCount":411,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/","name":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=","datePublished":"2025-07-10T21:09:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk2NSM3MDQwNjAzIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights-srpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights \u2013 SRPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868693"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}